General Information of DTT (ID: TTKMAZ6)

DTT Name Growth hormone receptor (GHR) DTT Info
Gene Name GHR

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
2 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pegvisomant DMDEZI3 Acromegaly 5A60.0 Approved [1]
Somatropin recombinant DMF3GM2 Fetal growth restriction KA20.1Z Approved [2]
------------------------------------------------------------------------------------
6 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
IONIS-GHR-LRx DMQ9711 Acromegaly 5A60.0 Phase 2 [3]
PH-794428 DM71HVW Growth hormone deficiency 5A61.3 Phase 2 [4]
SKF-110679 DMNRHMX Growth hormone deficiency 5A61.3 Phase 2 [5]
EP-51216 DM49RI7 Eating disorder 6B82 Phase 1 [6]
EP-51389 DMW739O Eating disorder 6B82 Phase 1 [6]
Syntropin DMH76KD Dwarfism 5B11 Phase 1 [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Clinical Trial Drug(s)
1 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
AOD-9604 DMGDPSI Obesity 5B81 Discontinued in Phase 2 [8]
------------------------------------------------------------------------------------
1 Preclinical Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
BVT-A DMDSX58 Acromegaly 5A60.0 Preclinical [9]
------------------------------------------------------------------------------------
1 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
NNC-26-0194 DMDCPFJ Discovery agent N.A. Investigative [10]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Growth hormone receptor antagonist treatment reduces exercise performance in young males. J Clin Endocrinol Metab. 2009 Sep;94(9):3265-72.
2 Cost-utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency in children. Curr Med Res Opin. 2006 Feb;22(2):351-7.
3 ClinicalTrials.gov (NCT04522180) An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherapy in Patients With Acromegaly. U.S.National Institutes of Health.
4 PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans.Xenobiotica.2008 Oct;38(10):1340-51.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1093).
6 Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
7 Late feedback effects of hypothalamic-pituitary-adrenal axis hormones in healthy subjects. Psychoneuroendocrinology. 1998 May;23(4):371-83.
8 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
9 Emerging drugs for acromegaly. Expert Opin Emerg Drugs. 2008 Jun;13(2):273-93.
10 Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998 Nov;28(11):1083-92.